| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Burkitt Lymphoma | 36 | 2025 | 57 | 9.810 |
Why?
|
| Malaria, Falciparum | 44 | 2025 | 119 | 9.420 |
Why?
|
| Plasmodium falciparum | 38 | 2025 | 134 | 7.100 |
Why?
|
| Epstein-Barr Virus Infections | 25 | 2025 | 89 | 6.750 |
Why?
|
| Herpesvirus 4, Human | 32 | 2025 | 178 | 6.620 |
Why?
|
| Kenya | 53 | 2025 | 79 | 3.090 |
Why?
|
| Merozoite Surface Protein 1 | 10 | 2016 | 20 | 2.290 |
Why?
|
| Antigens, Protozoan | 13 | 2025 | 43 | 2.070 |
Why?
|
| Malaria Vaccines | 8 | 2025 | 27 | 1.920 |
Why?
|
| Child, Preschool | 42 | 2025 | 1793 | 1.740 |
Why?
|
| Child | 49 | 2025 | 4189 | 1.700 |
Why?
|
| Malaria | 12 | 2017 | 101 | 1.620 |
Why?
|
| Sarcoma, Kaposi | 2 | 2023 | 15 | 1.520 |
Why?
|
| Interferon-gamma | 11 | 2017 | 551 | 1.430 |
Why?
|
| Antibodies, Protozoan | 12 | 2025 | 48 | 1.410 |
Why?
|
| Endemic Diseases | 13 | 2021 | 14 | 1.360 |
Why?
|
| Killer Cells, Natural | 3 | 2021 | 218 | 1.320 |
Why?
|
| Coinfection | 5 | 2020 | 44 | 1.200 |
Why?
|
| Interleukin-10 | 5 | 2016 | 149 | 1.200 |
Why?
|
| Infant | 28 | 2024 | 1492 | 1.090 |
Why?
|
| Adolescent | 34 | 2025 | 5838 | 1.050 |
Why?
|
| Herpesvirus 8, Human | 2 | 2023 | 16 | 1.020 |
Why?
|
| Humans | 100 | 2025 | 59389 | 0.990 |
Why?
|
| Genome, Viral | 3 | 2025 | 120 | 0.920 |
Why?
|
| Immune System | 2 | 2019 | 129 | 0.880 |
Why?
|
| Protozoan Proteins | 10 | 2017 | 86 | 0.800 |
Why?
|
| CD56 Antigen | 2 | 2020 | 15 | 0.770 |
Why?
|
| Seroepidemiologic Studies | 7 | 2023 | 48 | 0.750 |
Why?
|
| Immunoglobulin G | 14 | 2023 | 446 | 0.720 |
Why?
|
| Herpesviridae Infections | 1 | 2020 | 25 | 0.690 |
Why?
|
| Herpesviridae | 1 | 2020 | 14 | 0.690 |
Why?
|
| Viral Load | 9 | 2021 | 220 | 0.680 |
Why?
|
| Receptors, IgG | 1 | 2020 | 35 | 0.680 |
Why?
|
| Antibodies, Viral | 7 | 2024 | 292 | 0.660 |
Why?
|
| Sickle Cell Trait | 2 | 2013 | 7 | 0.650 |
Why?
|
| Genotype | 10 | 2024 | 617 | 0.640 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 3 | 2020 | 17 | 0.630 |
Why?
|
| Immunity, Humoral | 2 | 2016 | 37 | 0.630 |
Why?
|
| Tumor Virus Infections | 2 | 2016 | 37 | 0.610 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 10 | 2023 | 446 | 0.600 |
Why?
|
| Female | 40 | 2025 | 30726 | 0.580 |
Why?
|
| Parasitemia | 8 | 2016 | 35 | 0.580 |
Why?
|
| T-Lymphocytes | 5 | 2017 | 986 | 0.540 |
Why?
|
| Immunologic Surveillance | 1 | 2016 | 13 | 0.540 |
Why?
|
| Oncogenic Viruses | 1 | 2016 | 2 | 0.540 |
Why?
|
| Male | 30 | 2025 | 27749 | 0.520 |
Why?
|
| T-Lymphocyte Subsets | 4 | 2012 | 244 | 0.480 |
Why?
|
| Adult | 28 | 2025 | 15681 | 0.480 |
Why?
|
| Polymerase Chain Reaction | 9 | 2015 | 495 | 0.480 |
Why?
|
| Papillomavirus Infections | 3 | 2022 | 120 | 0.480 |
Why?
|
| Animals | 31 | 2023 | 19650 | 0.470 |
Why?
|
| Antimalarials | 5 | 2019 | 67 | 0.470 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2016 | 207 | 0.470 |
Why?
|
| Immunity, Cellular | 2 | 2013 | 171 | 0.460 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2014 | 439 | 0.450 |
Why?
|
| Survival Rate | 1 | 2016 | 801 | 0.440 |
Why?
|
| Cross-Sectional Studies | 8 | 2024 | 2382 | 0.420 |
Why?
|
| Neoplasms | 2 | 2016 | 1231 | 0.410 |
Why?
|
| Young Adult | 13 | 2025 | 4272 | 0.410 |
Why?
|
| Interleukin-6 | 1 | 2014 | 309 | 0.410 |
Why?
|
| HIV Infections | 5 | 2022 | 913 | 0.400 |
Why?
|
| Whole Genome Sequencing | 2 | 2025 | 63 | 0.400 |
Why?
|
| Cytokines | 3 | 2025 | 912 | 0.400 |
Why?
|
| Biomarkers | 2 | 2016 | 1307 | 0.380 |
Why?
|
| Vaccination | 3 | 2025 | 335 | 0.380 |
Why?
|
| Age Factors | 9 | 2020 | 1504 | 0.380 |
Why?
|
| Uterine Cervical Dysplasia | 2 | 2022 | 28 | 0.370 |
Why?
|
| Promoter Regions, Genetic | 1 | 2014 | 650 | 0.370 |
Why?
|
| CD8-Positive T-Lymphocytes | 5 | 2016 | 648 | 0.360 |
Why?
|
| Alleles | 7 | 2023 | 411 | 0.360 |
Why?
|
| Microbiota | 2 | 2023 | 103 | 0.360 |
Why?
|
| History, 21st Century | 4 | 2021 | 162 | 0.350 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2022 | 135 | 0.340 |
Why?
|
| Immunologic Memory | 4 | 2025 | 281 | 0.310 |
Why?
|
| B-Lymphocytes | 3 | 2025 | 550 | 0.310 |
Why?
|
| Tumor Escape | 1 | 2008 | 16 | 0.300 |
Why?
|
| Cancer Vaccines | 1 | 2008 | 45 | 0.300 |
Why?
|
| Family Characteristics | 1 | 2008 | 43 | 0.290 |
Why?
|
| Prevalence | 7 | 2014 | 1253 | 0.290 |
Why?
|
| Sensitivity and Specificity | 4 | 2025 | 1091 | 0.280 |
Why?
|
| Haplotypes | 5 | 2014 | 115 | 0.280 |
Why?
|
| Case-Control Studies | 4 | 2014 | 1051 | 0.250 |
Why?
|
| Virus Activation | 3 | 2011 | 23 | 0.250 |
Why?
|
| Genetic Variation | 3 | 2025 | 357 | 0.250 |
Why?
|
| Odds Ratio | 3 | 2020 | 746 | 0.250 |
Why?
|
| Middle Aged | 17 | 2024 | 16314 | 0.250 |
Why?
|
| Nanopores | 1 | 2025 | 10 | 0.240 |
Why?
|
| Viral Matrix Proteins | 1 | 2025 | 47 | 0.240 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2025 | 47 | 0.240 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2024 | 7 | 0.230 |
Why?
|
| Hepatitis B Antibodies | 1 | 2024 | 8 | 0.230 |
Why?
|
| Hepatitis B Vaccines | 1 | 2024 | 13 | 0.230 |
Why?
|
| Hepatitis B | 1 | 2024 | 28 | 0.230 |
Why?
|
| Immunoglobulin Class Switching | 1 | 2025 | 82 | 0.230 |
Why?
|
| Disease Models, Animal | 3 | 2023 | 2050 | 0.220 |
Why?
|
| History, 20th Century | 3 | 2021 | 224 | 0.220 |
Why?
|
| Saliva | 1 | 2024 | 100 | 0.220 |
Why?
|
| Glucosephosphate Dehydrogenase Deficiency | 1 | 2003 | 3 | 0.220 |
Why?
|
| Infant, Newborn | 9 | 2024 | 1284 | 0.220 |
Why?
|
| Pregnancy Complications, Parasitic | 2 | 2001 | 6 | 0.210 |
Why?
|
| Aflatoxins | 1 | 2022 | 1 | 0.210 |
Why?
|
| Nucleocapsid Proteins | 1 | 2023 | 35 | 0.210 |
Why?
|
| Placenta | 2 | 2001 | 55 | 0.200 |
Why?
|
| Aged | 12 | 2024 | 13408 | 0.200 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2023 | 200 | 0.200 |
Why?
|
| Rituximab | 1 | 2023 | 80 | 0.200 |
Why?
|
| Alphapapillomavirus | 1 | 2022 | 16 | 0.200 |
Why?
|
| Cell Line, Tumor | 2 | 2025 | 1368 | 0.200 |
Why?
|
| MicroRNAs | 2 | 2019 | 616 | 0.200 |
Why?
|
| Erythrocytes | 4 | 2014 | 146 | 0.200 |
Why?
|
| Gene Frequency | 3 | 2014 | 118 | 0.200 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2023 | 95 | 0.200 |
Why?
|
| RNA, Viral | 2 | 2019 | 259 | 0.190 |
Why?
|
| Flow Cytometry | 3 | 2020 | 645 | 0.190 |
Why?
|
| Receptors, KIR | 1 | 2021 | 3 | 0.190 |
Why?
|
| DNA, Viral | 2 | 2020 | 223 | 0.180 |
Why?
|
| Epitopes, T-Lymphocyte | 3 | 2022 | 176 | 0.180 |
Why?
|
| Dysbiosis | 1 | 2021 | 56 | 0.180 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2019 | 396 | 0.180 |
Why?
|
| Receptor, Macrophage Colony-Stimulating Factor | 1 | 2020 | 9 | 0.180 |
Why?
|
| Signaling Lymphocytic Activation Molecule Family | 1 | 2020 | 5 | 0.170 |
Why?
|
| Cells, Cultured | 3 | 2016 | 2092 | 0.170 |
Why?
|
| Parasites | 1 | 2020 | 10 | 0.170 |
Why?
|
| Africa South of the Sahara | 3 | 2015 | 16 | 0.170 |
Why?
|
| Mentors | 1 | 2021 | 116 | 0.170 |
Why?
|
| Longitudinal Studies | 4 | 2019 | 1189 | 0.170 |
Why?
|
| Fetal Growth Retardation | 1 | 1999 | 14 | 0.170 |
Why?
|
| Phenotype | 1 | 2023 | 1137 | 0.170 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2022 | 620 | 0.160 |
Why?
|
| Global Health | 1 | 2021 | 167 | 0.160 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2011 | 238 | 0.160 |
Why?
|
| Hemoglobin, Sickle | 2 | 2013 | 7 | 0.160 |
Why?
|
| Virus Replication | 2 | 2023 | 305 | 0.160 |
Why?
|
| Deferoxamine | 1 | 1999 | 4 | 0.160 |
Why?
|
| Iron Chelating Agents | 1 | 1999 | 6 | 0.160 |
Why?
|
| Sequence Analysis, DNA | 1 | 2020 | 394 | 0.160 |
Why?
|
| Time Factors | 4 | 2016 | 3617 | 0.150 |
Why?
|
| Viral Proteins | 1 | 2020 | 253 | 0.150 |
Why?
|
| Genome-Wide Association Study | 1 | 2020 | 331 | 0.150 |
Why?
|
| Massachusetts | 1 | 2024 | 2019 | 0.150 |
Why?
|
| Risk Factors | 6 | 2019 | 4986 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2014 | 676 | 0.150 |
Why?
|
| Incidence | 4 | 2016 | 1238 | 0.150 |
Why?
|
| HIV-1 | 2 | 2020 | 692 | 0.150 |
Why?
|
| Biomedical Research | 1 | 2021 | 256 | 0.150 |
Why?
|
| Immunotherapy | 1 | 2020 | 228 | 0.140 |
Why?
|
| Adenoviruses, Simian | 1 | 2017 | 1 | 0.140 |
Why?
|
| Mutation | 2 | 2017 | 2456 | 0.140 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2019 | 167 | 0.140 |
Why?
|
| Mice | 5 | 2023 | 10291 | 0.140 |
Why?
|
| Gene Expression Profiling | 2 | 2017 | 718 | 0.140 |
Why?
|
| Chronic Disease | 1 | 2020 | 717 | 0.140 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2016 | 90 | 0.130 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2016 | 56 | 0.130 |
Why?
|
| Cell Differentiation | 2 | 2021 | 1304 | 0.130 |
Why?
|
| RNA, Messenger | 3 | 2017 | 1466 | 0.130 |
Why?
|
| Antibody Formation | 1 | 2016 | 108 | 0.130 |
Why?
|
| Life Cycle Stages | 2 | 2013 | 15 | 0.130 |
Why?
|
| Pregnancy | 6 | 2024 | 2213 | 0.130 |
Why?
|
| Antigens, Viral | 3 | 2016 | 130 | 0.120 |
Why?
|
| Carcinogenesis | 1 | 2016 | 118 | 0.120 |
Why?
|
| Recurrence | 3 | 2012 | 602 | 0.120 |
Why?
|
| Protein Array Analysis | 1 | 2015 | 25 | 0.120 |
Why?
|
| Monitoring, Immunologic | 1 | 2015 | 3 | 0.120 |
Why?
|
| Population Surveillance | 1 | 2016 | 195 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 474 | 0.120 |
Why?
|
| Inflammation | 1 | 2021 | 1099 | 0.120 |
Why?
|
| Neoplasm Staging | 1 | 2016 | 448 | 0.120 |
Why?
|
| Artemisinins | 1 | 2014 | 13 | 0.120 |
Why?
|
| Biopsy | 1 | 2016 | 410 | 0.120 |
Why?
|
| Gene Expression Regulation | 3 | 2010 | 1552 | 0.110 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2025 | 263 | 0.110 |
Why?
|
| Blood | 1 | 2013 | 29 | 0.110 |
Why?
|
| DNA, Protozoan | 3 | 2012 | 35 | 0.110 |
Why?
|
| Risk | 1 | 2014 | 364 | 0.110 |
Why?
|
| Acute Disease | 1 | 2015 | 658 | 0.110 |
Why?
|
| Models, Biological | 2 | 2017 | 1143 | 0.110 |
Why?
|
| Cohort Studies | 2 | 2016 | 2375 | 0.100 |
Why?
|
| DNA Primers | 1 | 2013 | 289 | 0.100 |
Why?
|
| Age Distribution | 4 | 2007 | 249 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 402 | 0.100 |
Why?
|
| Models, Immunological | 1 | 2012 | 85 | 0.100 |
Why?
|
| Enzyme-Linked Immunospot Assay | 1 | 2012 | 11 | 0.100 |
Why?
|
| Immunodominant Epitopes | 2 | 2009 | 56 | 0.100 |
Why?
|
| Liver | 2 | 2013 | 795 | 0.100 |
Why?
|
| Models, Statistical | 1 | 2013 | 299 | 0.100 |
Why?
|
| Arbovirus Infections | 1 | 2011 | 3 | 0.090 |
Why?
|
| Hospital Mortality | 1 | 2016 | 842 | 0.090 |
Why?
|
| Polymorphism, Genetic | 3 | 2014 | 185 | 0.090 |
Why?
|
| Genetic Vectors | 1 | 2017 | 808 | 0.090 |
Why?
|
| Proportional Hazards Models | 3 | 2019 | 674 | 0.090 |
Why?
|
| Prospective Studies | 2 | 2016 | 3067 | 0.090 |
Why?
|
| Base Sequence | 1 | 2013 | 1302 | 0.090 |
Why?
|
| Peptide Library | 1 | 2010 | 35 | 0.090 |
Why?
|
| Malnutrition | 1 | 2010 | 40 | 0.090 |
Why?
|
| Computational Biology | 3 | 2019 | 333 | 0.080 |
Why?
|
| Immunoglobulin D | 2 | 2025 | 8 | 0.080 |
Why?
|
| Uganda | 1 | 2009 | 33 | 0.080 |
Why?
|
| Peptide Fragments | 2 | 2008 | 400 | 0.080 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2009 | 66 | 0.080 |
Why?
|
| Virus Latency | 1 | 2008 | 29 | 0.080 |
Why?
|
| Sporozoites | 1 | 2008 | 4 | 0.070 |
Why?
|
| Prognosis | 2 | 2025 | 1597 | 0.070 |
Why?
|
| Protein Subunits | 2 | 2009 | 165 | 0.070 |
Why?
|
| Epitope Mapping | 1 | 2008 | 46 | 0.070 |
Why?
|
| Fetal Blood | 1 | 2008 | 70 | 0.070 |
Why?
|
| Cluster Analysis | 2 | 2025 | 245 | 0.070 |
Why?
|
| Immunity, Innate | 2 | 2015 | 774 | 0.070 |
Why?
|
| RNA, Ribosomal, 18S | 1 | 2007 | 6 | 0.070 |
Why?
|
| Microspheres | 1 | 2007 | 55 | 0.070 |
Why?
|
| Housing | 1 | 2008 | 72 | 0.070 |
Why?
|
| Smallpox Vaccine | 1 | 2007 | 13 | 0.070 |
Why?
|
| Microscopy | 3 | 2015 | 90 | 0.070 |
Why?
|
| HLA-A2 Antigen | 1 | 2007 | 64 | 0.070 |
Why?
|
| Toll-Like Receptors | 1 | 2009 | 426 | 0.070 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2005 | 7 | 0.060 |
Why?
|
| Fluorescent Dyes | 1 | 2007 | 196 | 0.060 |
Why?
|
| Vincristine | 1 | 2005 | 25 | 0.060 |
Why?
|
| Membrane Glycoproteins | 1 | 2009 | 661 | 0.060 |
Why?
|
| Receptors, CXCR5 | 1 | 2025 | 2 | 0.060 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2025 | 24 | 0.060 |
Why?
|
| Macrolides | 1 | 2005 | 37 | 0.060 |
Why?
|
| Germinal Center | 1 | 2025 | 38 | 0.060 |
Why?
|
| Democratic Republic of the Congo | 1 | 2024 | 8 | 0.060 |
Why?
|
| Immunoassay | 1 | 2025 | 67 | 0.060 |
Why?
|
| Immunization Schedule | 1 | 2024 | 17 | 0.060 |
Why?
|
| Hepatitis B virus | 1 | 2024 | 13 | 0.060 |
Why?
|
| Bayes Theorem | 1 | 2025 | 110 | 0.060 |
Why?
|
| Tanzania | 1 | 2024 | 19 | 0.060 |
Why?
|
| Genes, MHC Class I | 1 | 2004 | 27 | 0.060 |
Why?
|
| Vaccines, Synthetic | 1 | 2004 | 68 | 0.060 |
Why?
|
| Genetics, Population | 1 | 2004 | 40 | 0.060 |
Why?
|
| Receptors, KIR3DL1 | 1 | 2023 | 5 | 0.050 |
Why?
|
| Feeding Methods | 1 | 2023 | 8 | 0.050 |
Why?
|
| Altitude | 1 | 2003 | 14 | 0.050 |
Why?
|
| Euphorbia | 1 | 2003 | 3 | 0.050 |
Why?
|
| Latex | 1 | 2003 | 5 | 0.050 |
Why?
|
| DNA Copy Number Variations | 1 | 2023 | 65 | 0.050 |
Why?
|
| Parturition | 1 | 2023 | 52 | 0.050 |
Why?
|
| Informed Consent | 1 | 2023 | 138 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2023 | 6071 | 0.050 |
Why?
|
| Papillomaviridae | 1 | 2022 | 58 | 0.050 |
Why?
|
| Serologic Tests | 1 | 2022 | 34 | 0.050 |
Why?
|
| Pregnant Women | 1 | 2023 | 84 | 0.050 |
Why?
|
| HLA Antigens | 1 | 2022 | 61 | 0.050 |
Why?
|
| Logistic Models | 2 | 2019 | 1234 | 0.050 |
Why?
|
| Residence Characteristics | 1 | 2003 | 215 | 0.050 |
Why?
|
| Dendritic Cells | 1 | 2005 | 515 | 0.050 |
Why?
|
| Biomarkers, Tumor | 1 | 2025 | 461 | 0.050 |
Why?
|
| Phylogeny | 1 | 2022 | 337 | 0.050 |
Why?
|
| Host-Pathogen Interactions | 1 | 2023 | 240 | 0.050 |
Why?
|
| Environmental Exposure | 1 | 2003 | 208 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2001 | 847 | 0.050 |
Why?
|
| Electrosurgery | 1 | 2020 | 3 | 0.040 |
Why?
|
| Receptors, CCR5 | 1 | 2001 | 56 | 0.040 |
Why?
|
| Cryotherapy | 1 | 2020 | 12 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2022 | 281 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2025 | 1559 | 0.040 |
Why?
|
| Hospitals | 1 | 2023 | 378 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2005 | 628 | 0.040 |
Why?
|
| Research Personnel | 1 | 2021 | 92 | 0.040 |
Why?
|
| Hemeproteins | 1 | 1999 | 16 | 0.040 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2019 | 46 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2022 | 266 | 0.040 |
Why?
|
| Obstetric Labor, Premature | 1 | 1999 | 31 | 0.040 |
Why?
|
| Human papillomavirus 16 | 1 | 2019 | 17 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 267 | 0.040 |
Why?
|
| Vagina | 1 | 2019 | 79 | 0.040 |
Why?
|
| Bacteria | 1 | 2021 | 278 | 0.040 |
Why?
|
| Sexual Partners | 1 | 2019 | 75 | 0.040 |
Why?
|
| United States | 2 | 2017 | 7426 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 1999 | 527 | 0.040 |
Why?
|
| Pregnancy Outcome | 1 | 1999 | 181 | 0.040 |
Why?
|
| Iron | 1 | 1999 | 136 | 0.040 |
Why?
|
| Membrane Proteins | 2 | 2015 | 850 | 0.040 |
Why?
|
| Adenovirus Infections, Human | 1 | 2017 | 2 | 0.040 |
Why?
|
| Gorilla gorilla | 1 | 2017 | 3 | 0.040 |
Why?
|
| Ghana | 1 | 2017 | 10 | 0.040 |
Why?
|
| Plasmodium yoelii | 1 | 2017 | 6 | 0.040 |
Why?
|
| Mutation Rate | 1 | 2017 | 19 | 0.030 |
Why?
|
| Transgenes | 1 | 2017 | 177 | 0.030 |
Why?
|
| Plasmids | 1 | 2017 | 279 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2017 | 193 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 2016 | 114 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2017 | 159 | 0.030 |
Why?
|
| Spleen | 1 | 2017 | 479 | 0.030 |
Why?
|
| Histocompatibility Testing | 2 | 2007 | 31 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2017 | 147 | 0.030 |
Why?
|
| Capsid Proteins | 1 | 2016 | 92 | 0.030 |
Why?
|
| Gene Expression | 1 | 1999 | 809 | 0.030 |
Why?
|
| Mitochondria | 1 | 1999 | 343 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2015 | 141 | 0.030 |
Why?
|
| Merozoites | 1 | 2015 | 1 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2017 | 868 | 0.030 |
Why?
|
| Macrophages | 1 | 2001 | 1015 | 0.030 |
Why?
|
| Molecular Epidemiology | 1 | 2014 | 25 | 0.030 |
Why?
|
| RNA Interference | 1 | 2017 | 590 | 0.030 |
Why?
|
| Amino Acid Sequence | 2 | 2008 | 1553 | 0.030 |
Why?
|
| Population Dynamics | 1 | 2013 | 17 | 0.030 |
Why?
|
| Cell Count | 1 | 2013 | 127 | 0.030 |
Why?
|
| Africa | 1 | 2012 | 21 | 0.030 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2012 | 14 | 0.030 |
Why?
|
| Host-Parasite Interactions | 1 | 2012 | 55 | 0.020 |
Why?
|
| Geography | 1 | 2012 | 32 | 0.020 |
Why?
|
| Adaptive Immunity | 1 | 2012 | 98 | 0.020 |
Why?
|
| Arthropod Vectors | 1 | 2011 | 2 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2011 | 34 | 0.020 |
Why?
|
| Disease Outbreaks | 1 | 2011 | 102 | 0.020 |
Why?
|
| Glutathione Peroxidase | 1 | 2010 | 27 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 409 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2014 | 5119 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2012 | 459 | 0.020 |
Why?
|
| Papua New Guinea | 1 | 2009 | 5 | 0.020 |
Why?
|
| North America | 1 | 2009 | 105 | 0.020 |
Why?
|
| Neprilysin | 1 | 2008 | 11 | 0.020 |
Why?
|
| Lymphocyte Subsets | 1 | 2008 | 36 | 0.020 |
Why?
|
| Antigens, CD19 | 1 | 2008 | 19 | 0.020 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2008 | 29 | 0.020 |
Why?
|
| Growth Inhibitors | 1 | 2008 | 25 | 0.020 |
Why?
|
| Molecular Weight | 1 | 2008 | 184 | 0.020 |
Why?
|
| Topography, Medical | 1 | 2007 | 2 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2017 | 2900 | 0.020 |
Why?
|
| Smallpox | 1 | 2007 | 9 | 0.020 |
Why?
|
| Vaccinia virus | 1 | 2007 | 70 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2007 | 486 | 0.020 |
Why?
|
| Bryostatins | 1 | 2005 | 1 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2005 | 65 | 0.020 |
Why?
|
| Jaw Neoplasms | 1 | 2004 | 2 | 0.010 |
Why?
|
| Abdominal Neoplasms | 1 | 2004 | 17 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2008 | 1951 | 0.010 |
Why?
|
| DNA Probes, HLA | 1 | 2004 | 1 | 0.010 |
Why?
|
| Linkage Disequilibrium | 1 | 2004 | 46 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2005 | 451 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2004 | 244 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 1479 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2003 | 450 | 0.010 |
Why?
|
| Algorithms | 1 | 2007 | 974 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2001 | 9 | 0.010 |
Why?
|
| Receptors, Chemokine | 1 | 2001 | 37 | 0.010 |
Why?
|
| Fetus | 1 | 2001 | 93 | 0.010 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2001 | 143 | 0.010 |
Why?
|
| CD4 Antigens | 1 | 2001 | 148 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2001 | 188 | 0.010 |
Why?
|
| Aging | 1 | 2004 | 710 | 0.010 |
Why?
|